American Journal of Cardiology
Volume 95, Issue 5 , Pages 558-564, 1 March 2005

Impact of nonfatal myocardial infarction on outcomes in patients with advanced heart failure and the effect of bucindolol therapy

  • Christopher M. O'Connor, MD

      Affiliations

    • Duke University Medical Center, Durham, North Carolina
    • Corresponding Author InformationAddress for reprints: Christopher M. O'Connor, MD, Division of Cardiology, Department of Medicine, Box 3356, Room 7401-A Duke North, Duke University Medical Center, Durham, North Carolina 27710.
    • ,
  • Steven Gottlieb, MD

      Affiliations

    • Baltimore VAMC, Baltimore, Maryland
    • ,
  • Jamieson M. Bourque, MD

      Affiliations

    • Duke University Medical Center, Durham, North Carolina
    • ,
  • Heidi Krause-Steinrauf, MS

      Affiliations

    • National Heart, Lung, and Blood Institute, Bethesda, Maryland
    • ,
  • Inder Anand, MD

      Affiliations

    • Minneapolis VAMC, Minneapolis, Minnesota
    • ,
  • Jeffrey L. Anderson, MD

      Affiliations

    • University of Utah Health Sciences Center, Salt Lake City, Utah
    • ,
  • Jonathan F. Plehn, MD

      Affiliations

    • National Heart, Lung, and Blood Institute, Bethesda, Maryland
    • ,
  • Marc A. Silver, MD

      Affiliations

    • Advocate Christ Medical Center, Oak Lawn, Illinois
    • ,
  • Michel White, MD

      Affiliations

    • Montreal Heart Institute, Montreal, Quebec, Canada
    • ,
  • Peter Carson, MD

      Affiliations

    • Washington, DC VAMC, Washington, DC
    • ,
  • BEST Investigators

Received 6 May 2004; accepted 29 October 2004.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 The β-Blocker Evaluation of Survival Trial was sponsored by the Division of Epidemiology and Clinical Applications of the National Heart, Lung and Blood Institute, Bethesda, Maryland and the Department of Veterans Affairs Cooperative Studies Program, Washington, DC, through an interagency agreement. Additional support was provided by Incara Pharmaceuticals Corporation, Durham, North Carolina, which also supplied bucindolol and placebo.

PII: S0002-9149(04)01770-9

doi:10.1016/j.amjcard.2004.11.001

American Journal of Cardiology
Volume 95, Issue 5 , Pages 558-564, 1 March 2005

Article Tools

* Image Usage & Resolution